We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Dr. Paula Granado Martínez, Biomedical Research in Melanoma (VHIR)
Immune-based therapies have dramatically changed the management of many types of cancers including melanoma. However, the lack of clear biomarkers for the response or resistance to immunotherapy makes it only effective in a limited fraction of patients. Therefore, there is an unmet need to better understand the molecular mechanisms governing tumor evasion to develop and administer the most effective cancer treatment. In this matter, not much is known on how oncogenic pathways influence the immune infiltrate and this might have a significant impact on therapies. Although RAS pathway activation is a central event in melanoma, the MAPK stress pathway plays an important role in several processes related to the melanoma development and progression, including the signaling of several cytokines that modulate and activate the immune system. Our data shows that spontaneous mouse tumors and human samples harbor genetic alterations in this pathway, including the upregulation of p38á. Importantly, p38á upregulation is associated to poor survival in an independent manner, and reduces the survival of patients harboring BRAFV600E and NRASQ61 mutations. Moreover, p38á regulates the expression of immuno-checkpoint molecules in tumor cells and limits the antitumoral cytotoxic response modifying specific immune cell populations of tumor inflammatory infiltrates, possibly determining the response to immunotherapy. Therefore, our results suggest that inhibition of p38á or its downstream effectors in combination with immune-based therapies could be used as a new therapeutic approach for the treatment of melanoma.
Host: Dr. Juan Ángel Recio, Biomedical Research in Melanoma (VHIR)
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.